Orphanet Journal of Rare Diseases | Longitudinal Characteristics and Risk Factors of Asymptomatic Aspiration in Niemann-Pick Disease Type C1

Recommend:

This study reveals the covert characteristics of dysphagia during the progression of NPC1, providing critical evidence for developing early intervention strategies for dysphagia and selecting endpoints for experimental therapies.

 

Overview

This article, "Aspiration and silent aspiration in Niemann-Pick disease type C1: longitudinal findings from the NIH natural history study," published in the Orphanet Journal of Rare Diseases, systematically explores the incidence, longitudinal evolution, and association with neurological severity of overt and silent aspiration in patients with Niemann-Pick disease type C1 (NPC1).

Background

NPC1 is a rare neurodegenerative disease whose core pathogenic mechanism involves cholesterol transport defects leading to the accumulation of unesterified cholesterol in lysosomes. This study aims to address the clinical pain point where aspiration pneumonia is a major cause of death in NPC1 patients but lacks early warning signals. Currently, assessments of swallowing function rely heavily on bedside clinical examinations, which struggle to detect silent aspiration lacking a cough reflex, constituting a bottleneck in clinical monitoring. The research focuses on utilizing the National Institutes of Health (NIH) natural history study cohort, employing Video Fluoroscopic Swallowing Studies (VFSS) combined with the NIH-PAS scale to deeply analyze the longitudinal relationship between silent aspiration and NPC1 Neurological Severity Score (NSS) and Annual Severity Increment Score (ASIS), thereby identifying high-risk populations.

 

Mouse Phenotype Predict: Before designing [[NPC1]] animal model experiments, use this tool to preliminarily predict potential neurodegenerative phenotypes and swallowing dysfunction characteristics resulting from gene knockout, optimizing experimental design.

Learn More

 

Methods and Core Experiments

The authors conducted a longitudinal analysis of 130 confirmed patients enrolled in the NIH NPC1 natural history study between 2006 and 2024. The research team employed speech-language pathology assessments to conduct VFSS on patients suspected of having swallowing dysfunction, using the NIH-PAS scale to quantify aspiration risk. Silent aspiration was defined as aspiration observed during VFSS without clinical signs such as coughing, throat clearing, or wet voice. Using generalized linear models, researchers analyzed the impact of demographic characteristics, duration of neurological symptoms, history of epilepsy, body mass index, Miglustat usage, and NSS subscale scores (including swallowing, speech, motor function, etc.) on the occurrence of aspiration.

Key Conclusions and Perspectives

• Silent aspiration is extremely common in NPC1 patients; 24 out of 130 participants (18.4%) experienced at least one episode of silent aspiration, and 50% of patients showed recurrent episodes during follow-up.
• The occurrence of silent aspiration is highly correlated with the severity of neurological disease rather than the age-of-onset phenotype; total NSS score, elevated ASIS score, and history of epilepsy are significant independent risk factors.
• The use of Miglustat showed a protective effect against silent aspiration in the overall cohort, but no significant effect was observed in the pediatric subgroup (<20 years), suggesting that treatment response may be age-dependent.
• Lower weight percentiles in pediatric patients are associated with a higher risk of aspiration, indicating that nutritional status monitoring can serve as an early biomarker for disease progression.
• The average time from the onset of neurological symptoms to the occurrence of silent aspiration is approximately 10 years, providing a critical "time window" for clinical intervention.

Significance and Outlook

These findings have profound implications for drug development and clinical monitoring in NPC1. The study confirms that bedside examinations may underestimate aspiration risk; therefore, it is recommended to routinely introduce instrumental assessments like VFSS in patients with elevated NSS or ASIS scores, a history of epilepsy, or weight loss. This strategy facilitates early intervention before the onset of aspiration pneumonia, such as adjusting diet texture or managing feeding. Furthermore, incorporating swallowing function metrics as endpoints in NPC1 treatment trials can more accurately evaluate the improvement in quality of life and survival rates provided by disease-modifying therapies.

 

Pathogenicity: Evaluate the pathogenic likelihood of [[NPC1]] gene variants causing cholesterol transport defects, providing functional reference for analyzing the correlation between patient genotypes and the [[silent aspiration]] phenotype.

Learn More

 

Conclusion

Through large-scale longitudinal data analysis, this study establishes silent aspiration as a core feature of NPC1 disease progression, breaking the traditional cognition of relying solely on clinical symptoms to judge swallowing safety. For the NPC1 care system, establishing an active monitoring mechanism based on NSS and ASIS scores is crucial. The study suggests that as neurological function declines, the loss of protective reflexes often precedes obvious motor disorders, making silent aspiration a latent fatal threat. Future clinical practice should emphasize multidisciplinary collaboration, incorporating instrumental swallowing assessments into routine follow-ups, and combining Miglustat drug therapy with nutritional support to delay swallowing function deterioration, reduce the risk of pulmonary complications, and improve patient prognosis. This discovery provides a solid evidence-based foundation for precision nursing and clinical trial design in the field of rare diseases.

 

Beth I Solomon, Andrea M Munoz, Aiden Borruso, An Dang Do, and Forbes D Porter. Aspiration and silent aspiration in Niemann-Pick disease type C1: longitudinal findings from the NIH natural history study. Orphanet Journal of Rare Diseases.